Loading
Led SWOG S1801, the trial that showed giving pembrolizumab before surgery, not just after, improves outcomes in melanoma.
Sapna Patel was principal investigator of SWOG S1801, which showed that splitting pembrolizumab into neoadjuvant and adjuvant doses improves event-free survival compared with the same total drug given only after surgery in stage III-IV melanoma, a proof of the neoadjuvant principle with the same agent. She chairs the SWOG melanoma committee and leads uveal melanoma trials.
| Title | Journal | Year |
|---|---|---|
| Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma (SWOG S1801) | NEJM | 2023 |
| Neoadjuvant immunotherapy for melanoma: the path forward | Nature Reviews Clinical Oncology | 2023 |
Shares Stage III melanoma (after surgery), PD-1, Melanoma, Immune checkpoint inhibitors and the tags melanoma, neoadjuvant.
Shares Nature Reviews Clinical Oncology, PD-1, Melanoma, Pembrolizumab and the tag melanoma.
Shares Melanoma, Immune checkpoint inhibitors and the tags melanoma, neoadjuvant.
Shares Stage III melanoma (after surgery), PD-1, Melanoma, Pembrolizumab and the tag melanoma.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag neoadjuvant.
Shares PD-1, Melanoma, Pembrolizumab, Immune checkpoint inhibitors and the tag melanoma.
Shares Uveal melanoma, Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag neoadjuvant.